AsymBio has begun commercial production at its Shanghai Fengxian Commercial Manufacturing Base. It expands the company's integrated, end-to-end biologics CDMO services and reinforces its commitment to accelerating the commercialisation of innovative therapies worldwide.

Building on its Shanghai Jinshan Base and Zhangjiang Centre for Biological Technology and Innovation, the 130,000-square-metre Fengxian facility serves as a strategic hub within AsymBio's global network. It is designed to provide flexible and scalable support across all clinical phases, enabling tailored CDMO solutions from early development through commercial production.

The Fengxian base is equipped to manufacture a broad portfolio of next-generation biotherapeutics, including ADCs, dual-payload ADCs, RDCs, APCs, PDCs, AOCs, as well as monoclonal, bispecific, and multispecific antibodies and recombinant proteins.

Phase IA is dedicated to antibody manufacturing, featuring single-use bioreactors (200L, 500L, and 2000L) with a total drug substance capacity of 66,000 liters. A 20 m² lyophilizer supports production of up to one million vials of lyophilized antibody drug product annually.

Phase IB is focused on bioconjugate manufacturing, equipped with 200L and 500L reactors for all clinical phases. The drug product area includes clinical-scale lines (10 m² and 15 m² lyophilizers) and commercial-scale lines (two 20 m² lyophilizers), enabling annual output of up to two million vials.

Rui Yang, CEO, AsymBio, stated, "The launch of our Fengxian Base marks a strategic milestone in AsymBio's global expansion. By integrating our Jinshan and Fengxian hubs, we significantly enhance production capacity and service capabilities, delivering efficient, reliable solutions to clients worldwide. This facility strengthens supply chain resilience and reaffirms our commitment to advancing biopharmaceutical innovation."

The Fengxian facility operates under a quality management system that is designed to meet the standards of major global regulatory authorities. It employs advanced biomanufacturing technology that facilitates cost reduction and more flexible solutions compared to the traditional stainless-steel system. The site also adheres to Asymchem's ESG strategy and EHS management principles.